Preview Mode Links will not work in preview mode

Apr 20, 2020

A roundtable discussion about prostate cancer featuring perspectives from Drs Neeraj Agarwal, Emmanuel S Antonarakis and A Oliver Sartor.

  • Integrating PARP inhibitors into the treatment algorithm for patients with prostate cancer (PC) (00:00)
  • Role of PARP enzymes in DNA damage repair and mechanism of action of PARP inhibitors (04:25)
  • Genetic testing for patients with PC (06:31)
  • Correlation between Gleason score and incidence of DNA repair gene mutations in patients with localized PC (11:24)
  • Role of platinum-based chemotherapy for patients with PC and DNA repair gene mutations (15:34)
  • Sequencing PARP inhibitors and chemotherapy for patients with PC and DNA repair gene mutations(19:40)
  • Case (Dr Antonarakis): A man in his mid-40s with castration-resistant PC (CRPC), a BRCA2 mutation and lung metastases attains an excellent response to olaparib on a clinical trial (23:28)
  • Tolerability and side effects of PARP inhibitors (27:59)
  • Case (Dr Antonarakis): A man in his late 40s with metastatic hormone-sensitive PC and biallelic BRCA2 mutations receives PARP inhibitor monotherapy on a clinical trial (35:21)
  • Perspective on the potential use of PARP inhibitor monotherapy in the first-line setting for patients with hormone-sensitive PC and DNA repair gene mutations (39:49)
  • Tolerability of PARP-inhibitor monotherapy in the first-line setting (45:11)
  • Case (Dr Sartor): A man in his late 60s with metastatic CRPC (mCRPC) and a germline BRCA2 mutation receives olaparib (49:08)
  • Dosing and PARP trapping activity of PARP inhibitors (51:39)
  • Case (Dr Agarwal): A man in his late 60s with progressive mCRPC is enrolled on the TALAPRO-2 trial of enzalutamide with or without talazoparib (55:07)
  • Efficacy and tolerability of PARP inhibitors alone or in combination with endocrine therapy (59:32)
  • Response to PARP inhibitors in patients with PALB2, FANCA and RAD51 mutations; clinical care of patients with PC during the COVID-19 pandemic (1:03:48)

CME information and select publications